sorafenib has been researched along with uracil in 7 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (uracil) | Trials (uracil) | Recent Studies (post-2010) (uracil) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 11,300 | 715 | 2,532 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Kerbel, RS; Lee, CR; Man, S; Tang, TC; Xu, P | 1 |
Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC | 1 |
Homma, Y; Kaneko, T; Matsushima, H; Morimoto, H; Tsuzaka, Y | 1 |
Emmenegger, U; Francia, G; Hashimoto, K; Kerbel, RS; Man, S; Tang, TC; Xu, P | 1 |
Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW | 1 |
Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M | 1 |
Ding, X; Liu, Y; Lo, WS; Ng, KK; Wan, HL; Wong, AM; Wong, N; Xu, M; You, W | 1 |
2 trial(s) available for sorafenib and uracil
Article | Year |
---|---|
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tegafur; Uracil | 2010 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Feasibility Studies; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Sorafenib; Tegafur; Uracil; Young Adult | 2011 |
5 other study(ies) available for sorafenib and uracil
Article | Year |
---|---|
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Doxorubicin; Female; Humans; Injections, Subcutaneous; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tegafur; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2010 |
[Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Tomography, X-Ray Computed; Uracil | 2010 |
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Time Factors; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2010 |
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Topics: 2-Naphthylamine; Aged; Anilides; Antineoplastic Agents; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sorafenib; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; NF-kappa B; Nucleotides; Pyrophosphatases; Sorafenib; Uracil | 2022 |